By Professor Gail Matthews

Journal articles

Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253

Darley D; Matthews G; Dore G; Wilhelm K; Plit M; Stone E; Byrne A; Tonga K; Andresen D; Kelleher A; Cysique L; Cunningham P; Brew B, 2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963

Archer O; Perram J; Nadel J; Emmanuel S; Matthews G; Beresford R; Holloway CJ, 2021, 'Patients Living with HIV and Coronary Disease: Are we Using Appropriate Anti platelets as Part of Dual Antiplatelet Therapy?', Cardiology & Vascular Research, 5, http://dx.doi.org/10.33425/2639-8486.1094

Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038

Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE, 2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 6, pp. 39 - 56, http://dx.doi.org/10.1016/S2468-1253(20)30303-4

Phetsouphanh C; Darley D; Wilson D; Howe A; Ling Munier M; Patel S; Juno J; Burrell L; Kent S; Dore G; Kelleher A; Matthews G, 2021, 'Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection', , http://dx.doi.org/10.1101/2021.06.01.21257759

Darley DR; Dore GJ; Byrne A; Plit M; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort', , http://dx.doi.org/10.1101/2021.03.29.21254211

Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffman M; Pöhlmann S; Dwyer DE; Rockett R; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2020, 'SARS-CoV-2 neutralizing antibodies; longevity, breadth, and evasion by emerging viral variants', , http://dx.doi.org/10.1101/2020.12.19.20248567

Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ, 2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, 222, pp. S758 - S772, http://dx.doi.org/10.1093/infdis/jiaa366

Vogel JP; Tendal B; Giles M; Whitehead C; Burton W; Chakraborty S; Cheyne S; Downton T; Fraile Navarro D; Gleeson G; Gordon A; Hunt J; Kitschke J; McDonald S; McDonnell N; Middleton P; Millard T; Murano M; Oats J; Tate R; White H; Elliott J; Roach V; Homer CSE; McGowan S; Ballenden N; Barrett TL; Beavis V; Saunders JB; Buchanan T; Buchanan-Grey M; Casey D; Cowie M; Doyle J; Frydenberg M; Gnjidic D; Green S; Greenland R; Griffin K; Groombridge S; Hardy L; Hodak A; Holley A; Jovanovska V; Knight S; Michaels K; Morley P; Morphet J; Nou S; Russo P; Sarson M; Young A; Norris S; Morris-Donovan B; Gurry S; Hudson E; Hurley S; Primmer D; Timms S; Whicker S; Mukherjee S; Agostino J; Booth K; Burr L; Byers L; Cameron P; Cooper M; Cheng A; Fowler P; Glanville A; Leder K; McGloughlin S; McMullan B; McPhee E; Mitchell B; Morgan M; Myles P; O’Donnell C; Parr M; Phillips J; Randall R; Varndell W; Whyte I; William L; Brightwell R; Condon L; Deshpande A; Ehm A; Ferrie M; Muller J; Pullin L; Robinson E; Witt A; Larkins S; Morgan M; Taylor G; Agostino J; Burgess P; Agar M; Peiris D; Pearson S; Matthews G; McCarthy S, 2020, 'Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce', Australian and New Zealand Journal of Obstetrics and Gynaecology, 60, pp. 840 - 851, http://dx.doi.org/10.1111/ajo.13270

Dore GJ; Danta M; Matthews GV, 2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', The Lancet Gastroenterology and Hepatology, 5, pp. 1028 - 1029, http://dx.doi.org/10.1016/S2468-1253(20)30270-3

Boesecke C; Boyd A; Rauch A; Lacombe K; Rodger A; Pharris A; Pozniak A; Rijnders B; Smit C; Smith C; Hoornenborg E; Wedemeyer H; Schinkel J; Nerlander L; Duffell E; Noori T; Berenguer J; Peters L; Cotte L; Salazar-Vizcaya L; Puoti M; Parczewski M; Martin N; Ingiliz P; Zandkuijl P; Dressler S; Naggie S; van de Laar T; Reiberger T; Matthews G; Bhagani S; Prins M; Rockstroh JK, 2020, 'Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel (vol 34, pg 1699, 2020)', AIDS, 34, pp. 2161 - 2163, http://dx.doi.org/10.1097/01.aids.0000721220.20643.93

Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; DÁngio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL; Arias AA; Darley D; Matthews G, 2020, 'Autoantibodies against type I IFNs in patients with life-threatening COVID-19', Science, 370, pp. eabd4585, http://dx.doi.org/10.1126/science.abd4585

Zhang Q; Liu Z; Moncada-Velez M; Chen J; Ogishi M; Bigio B; Yang R; Arias AA; Zhou Q; Han JE; Ugurbil AC; Zhang P; Rapaport F; Li J; Spaan AN; Boisson B; Boisson-Dupuis S; Bustamante J; Puel A; Ciancanelli MJ; Zhang SY; Béziat V; Jouanguy E; Abel L; Cobat A; Casanova JL; Bastard P; Korol C; Rosain J; Philippot Q; Chbihi M; Lorenzo L; Bizien L; Neehus AL; Kerner G; Seeleuthner Y; Manry J; Le Voyer T; Le Voyer T; Le Pen J; Schneider WM; Razooky BS; Hoffmann HH; Michailidis E; Rice CM; Sabli IKD; Hodeib S; Sancho-Shimizu V; Bilguvar K; Ye J; Maniatis T; Bolze A; Zhang Y; Notarangelo LD; Su HC; Onodi F; Korniotis S; Karpf L; Soumelis V; Bonnet-Madin L; Amara A; Dorgham K; Gorochov G; Smith N; Duffy D; Moens L; Meyts I; Meade P; Darley D; Tangye S; Matthews G, 2020, 'Inborn errors of type I IFN immunity in patients with life-threatening COVID-19', Science, 370, pp. eabd4570, http://dx.doi.org/10.1126/science.abd4570

Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985

Han WM; Colby DJ; Khlaiphuengsin A; Apornpong T; Kerr SJ; Ubolyam S; Kroon E; Phanuphak N; Vasan S; Matthews GV; Avihingsanon A; Ruxrungtham K; Phanuphak P; Tangkijvanich P, 2020, 'Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand', Liver International, 40, pp. 2104 - 2109, http://dx.doi.org/10.1111/liv.14578

Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J, 2020, 'Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?', Journal of Acquired Immune Deficiency Syndromes, 84, pp. 527 - 533, http://dx.doi.org/10.1097/QAI.0000000000002386

Gorstein E; Martinello M; Churkin A; Dasgupta S; Walsh K; Applegate TL; Yardeni D; Etzion O; Uprichard SL; Barash D; Cotler SJ; Matthews GV; Dahari H, 2020, 'Modeling based response guided therapy in subjects with recent hepatitis C infection', Antiviral Research, 180, http://dx.doi.org/10.1016/j.antiviral.2020.104862

Valerio H; Alavi M; Matthews G; Law M; McManus H; Amin J; Janjua N; Krajden M; Tillakeratne S; Gleeson V; George J; Degenhardt L; Grebely J; Dore G, 2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC; Anderson S; McQuilton Z; Venkatesh B; Hammond N; Jha V; Burston VJ; McMahon J; Charles P; Commons R; O'Brien D; Mahoney A; Sheffield D; Lim LL; Gardiner B; Schulz T; Torresi J; Chean R; Sasadeusz J; Rogers B; Aboltins C; Singh K; Yong M; Lister D; Visvanathan K; Molton J; Tai A; Chalmers R; Martinello M; Wilson P; Gray T; Coghill S; Foo H; Sud A; Williams J; Lwin N; Post J; Van Haal S; Sullivan R; Matthews G; Kwan BCH; Slack A; Shum O; Cochrane B; Dotel R; Gilbey T; Mina M; Su Y; Trethewy C; Hudson B; Chatterji A; Mostert C; New D; Raby E; Hui S; Robinson O; Hart J; Tan SJ; Arellano A; Chambers J; Davis J; Rafiei N; Smith S; Sehu M; Da Silva J; Griffin P; Henderson A; Chaw K; Choong K; Burke A; Heather C; Senanayake S; Boyd M; Rowe E; Anagnostou M; Trad A; Ratcliff A; Dummer J; Bhally H; Giola M; Grimwade K; Chang CLL; Verrall A; Hogg S; Restropo D; Maze M; Ritchie S; Gedye C; Chang J, 2020, 'The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial', Trials, 21, http://dx.doi.org/10.1186/s13063-020-04576-9

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003

Bradshaw D; Vasylyeva TI; Davis C; Pybus OG; Thézé J; Thomson EC; Martinello M; Matthews GV; Burholt R; Gilleece Y; Cooke GS; Page EE; Waters L; Nelson M, 2020, 'Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England', Journal of Viral Hepatitis, 27, pp. 721 - 730, http://dx.doi.org/10.1111/jvh.13286

Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151

Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101

Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633

Dore GJ; Matthews GV, 2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8

Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010

Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164

Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562

Hall S; Burns G; Levy M; Lubel J; Nicoll A; Matthews G; Desmond P; Sievert W; Bowden S; Locarnini S; Holmes J; Visvanathan K; Thompson A, 2020, 'A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare', Journal of Hepatology, 73, pp. S69 - S70, http://dx.doi.org/10.1016/s0168-8278(20)30674-7

Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2

Revill PA; Chisari FV; Block JM; Dandri M; Gehring AJ; Guo H; Hu J; Kramvis A; Lampertico P; Janssen HLA; Levrero M; Li W; Liang TJ; Lim SG; Lu F; Penicaud MC; Tavis JE; Thimme R; Arbuthnot P; Boonstra A; Chang KM; Chen PJ; Glebe D; Guidotti LG; Fellay J; Ferrari C; Jansen L; Lau DTY; Lok AS; Maini MK; Mason W; Matthews G; Paraskevis D; Petersen J; Rehermann B; Shin EC; Thompson A; van Bömmel F; Wang FS; Watashi K; Yang HC; Yuan Z; Yuen MF; Block T; Miller V; Protzer U; Bréchot C; Locarnini S; Peters MG; Schinazi RF; Zoulim F, 2019, 'A global scientific strategy to cure hepatitis B', The Lancet Gastroenterology and Hepatology, 4, pp. 545 - 558, http://dx.doi.org/10.1016/S2468-1253(19)30119-0

Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016

Martinello M; Matthews GV, 2019, 'Management of acute HCV in the era of direct-acting antivirals: implications for elimination', The Lancet Gastroenterology and Hepatology, 4, pp. 256 - 257, http://dx.doi.org/10.1016/S2468-1253(19)30001-9

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3

Dore G; Feld J; Thompson A; Martinello M; Muir A; Agarwal K; Mullhaupt B; Wedemeyer H; Lacombe K; Matthews G; Schultz M; Mercade GE; Kho D; Filep E; Petoumenos K; Marks P; Tatsch F; dos Santos AGP; Gane E, 2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3

Dharan NJ; Neuhaus J; Rockstroh JK; Peters L; Gordin F; Arenas-Pinto A; Emerson C; Marks K; Hidalgo J; Sarmento-Castro R; Stephan C; Kumarasamy N; Emery S; Matthews GV, 2019, 'Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial', Hepatology, 69, pp. 1135 - 1150, http://dx.doi.org/10.1002/hep.30296

Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222

Lockart I; Matthews GV; Danta M, 2019, 'Sexually transmitted hepatitis C infection: The evolving epidemic in HIV-positive and HIV-negative MSM', Current Opinion in Infectious Diseases, 32, pp. 31 - 37, http://dx.doi.org/10.1097/QCO.0000000000000515

Layton C; Richmond J; Baker D; Owen L; Matthews G; Oliver-Landry E; Howell J; Doyle J, 2019, 'Eliminating hepatitis C: Part 2. Assessing your patient for antiviral treatment', Medicine Today, 20, pp. 24 - 32

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3

Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthews G, 2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9

Santen DV; Hoy J; Agius P; Iser D; O'reilly M; Sasadeusz J; Stoove M; Roney J; Moore R; Bk T; Medland N; Fairley C; Gane E; Matthews G; Prins M; Hellard M; Doyle J, 2019, 'THU-098-Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?', Journal of Hepatology, 70, pp. e204 - e204, http://dx.doi.org/10.1016/s0618-8278(19)30379-2

Khaw C; Richardson D; Matthews G; Read T, 2018, 'Looking at the positives: Proactive management of STIs in people with HIV', AIDS Research and Therapy, 15, http://dx.doi.org/10.1186/s12981-018-0216-9

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917

Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV, 2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy033

Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5

Back to profile page